Rigel Pharmaceuticals Files 8-K on Financials

Ticker: RIGL · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1034842

Rigel Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyRigel Pharmaceuticals Inc (RIGL)
Form Type8-K
Filed DateMar 4, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Rigel Pharma dropped an 8-K on March 4th about their financials - check it for the latest numbers.

AI Summary

Rigel Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. No specific financial figures or operational details were provided in the initial filing document.

Why It Matters

This filing provides an update on Rigel Pharmaceuticals' financial health and operational results, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate indication of significant negative events.

Key Players & Entities

  • Rigel Pharmaceuticals, Inc. (company) — Registrant
  • March 4, 2025 (date) — Date of earliest event reported
  • 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
  • South San Francisco, CA (location) — Principal executive offices location
  • 94080 (zip_code) — Principal executive offices zip code
  • (650) 624-1100 (phone_number) — Registrant's telephone number

FAQ

What specific financial results are being reported in this 8-K filing?

The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific financial figures are not detailed in the provided text.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is March 4, 2025.

Where are Rigel Pharmaceuticals' principal executive offices located?

Rigel Pharmaceuticals' principal executive offices are located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.

What is the registrant's telephone number?

The registrant's telephone number is (650) 624-1100.

What is the Commission File Number for Rigel Pharmaceuticals?

The Commission File Number for Rigel Pharmaceuticals is 0-29889.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.